These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22768342)

  • 1. Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.
    Ammar FF; Abdel-Azeim S; Zargarian L; Hobaika Z; Maroun RG; Fermandjian S
    PLoS One; 2012; 7(7):e40223. PubMed ID: 22768342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets.
    Arora R; de Beauchene IC; Polanski J; Laine E; Tchertanov L
    J Mol Recognit; 2013 Sep; 26(9):383-401. PubMed ID: 23836466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
    Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
    J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.
    Depatureaux A; Quashie PK; Mesplède T; Han Y; Koubi H; Plantier JC; Oliveira M; Moisi D; Brenner B; Wainberg MA
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7141-50. PubMed ID: 25224008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
    Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
    J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
    Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
    Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
    Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
    Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex.
    Bera S; Pandey KK; Vora AC; Grandgenett DP
    J Mol Biol; 2011 Jul; 410(5):831-46. PubMed ID: 21295584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
    Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
    Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
    Johnson BC; Métifiot M; Pommier Y; Hughes SH
    Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
    Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
    Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P
    Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
    Savarino A
    Retrovirology; 2007 Mar; 4():21. PubMed ID: 17374162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
    Métifiot M; Johnson B; Smith S; Zhao XZ; Marchand C; Burke T; Hughes S; Pommier Y
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5127-33. PubMed ID: 21876054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.
    Dicker IB; Samanta HK; Li Z; Hong Y; Tian Y; Banville J; Remillard RR; Walker MA; Langley DR; Krystal M
    J Biol Chem; 2007 Oct; 282(43):31186-96. PubMed ID: 17715137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors.
    Carcelli M; Bacchi A; Pelagatti P; Rispoli G; Rogolino D; Sanchez TW; Sechi M; Neamati N
    J Inorg Biochem; 2013 Jan; 118():74-82. PubMed ID: 23123342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance.
    Dewdney TG; Wang Y; Kovari IA; Reiter SJ; Kovari LC
    J Struct Biol; 2013 Nov; 184(2):245-50. PubMed ID: 23891838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.
    Bona R; Baroncelli S; D'Ettorre G; Andreotti M; Ceccarelli G; Filati P; Leone P; Blasi M; Michelini Z; Galluzzo CM; Mallano A; Vullo V; Cara A
    AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1365-9. PubMed ID: 23802629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
    Bar-Magen T; Sloan RD; Faltenbacher VH; Donahue DA; Kuhl BD; Oliveira M; Xu H; Wainberg MA
    Retrovirology; 2009 Nov; 6():103. PubMed ID: 19906306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.